Cutera (NASDAQ:CUTR) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of Cutera (NASDAQ:CUTR) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the medical device company’s stock.

CUTR has been the subject of a number of other reports. Piper Sandler restated a “neutral” rating and issued a $1.00 price target (down from $3.00) on shares of Cutera in a report on Friday, August 9th. Stephens reduced their target price on Cutera from $10.00 to $5.00 and set an “overweight” rating for the company in a research note on Friday, August 9th.

Cutera Stock Up 2.8 %

Shares of CUTR stock opened at $0.33 on Tuesday. The firm has a 50 day moving average of $0.61 and a 200-day moving average of $1.15. The company has a market cap of $6.57 million, a price-to-earnings ratio of -0.05 and a beta of 1.35. Cutera has a 52 week low of $0.28 and a 52 week high of $4.97.

Hedge Funds Weigh In On Cutera

A number of large investors have recently modified their holdings of the company. Bayesian Capital Management LP bought a new stake in Cutera during the 1st quarter valued at $33,000. Ground Swell Capital LLC acquired a new position in shares of Cutera during the second quarter valued at about $37,000. Bank of Montreal Can increased its position in shares of Cutera by 14.2% during the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock worth $455,000 after acquiring an additional 35,248 shares in the last quarter. Finally, Squarepoint Ops LLC raised its holdings in shares of Cutera by 164.5% in the 2nd quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock worth $172,000 after acquiring an additional 70,870 shares during the last quarter. 90.70% of the stock is currently owned by institutional investors.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.